WS Investor
29 Jan 2026, 17:08
Thermo Fisher Scientific reported solid fourth-quarter and full-year 2025 results, highlighting steady growth, strong execution, and active capital deployment.
In the fourth quarter, revenue rose 7% year over year to $12.21 billion, while GAAP diluted EPS increased 9% to $5.21 and adjusted EPS climbed 8% to $6.57. Operating performance remained robust, with GAAP operating margin improving to 18.5%. For the full year, revenue grew 4% to $44.56 billion, GAAP diluted EPS increased 7% to $17.74, and adjusted EPS rose 5% to $22.87.
The company underscored progress in its long-term growth strategy through major product launches across mass spectrometry, cryo-electron microscopy, lab automation, and bioprocessing, alongside regulatory approvals in diagnostics. Thermo Fisher also strengthened its strategic position through partnerships, including a collaboration with OpenAI to expand AI use across operations and products.
Capital deployment was a key theme in 2025, with approximately $16.5 billion deployed, including $13 billion in acquisitions and $3.6 billion returned to shareholders via buybacks and dividends. Management said the company enters 2026 from a position of strength, supported by its growth strategy, operational discipline, and expanding capabilities across biopharma, diagnostics, and scientific research.
In the fourth quarter, revenue rose 7% year over year to $12.21 billion, while GAAP diluted EPS increased 9% to $5.21 and adjusted EPS climbed 8% to $6.57. Operating performance remained robust, with GAAP operating margin improving to 18.5%. For the full year, revenue grew 4% to $44.56 billion, GAAP diluted EPS increased 7% to $17.74, and adjusted EPS rose 5% to $22.87.
The company underscored progress in its long-term growth strategy through major product launches across mass spectrometry, cryo-electron microscopy, lab automation, and bioprocessing, alongside regulatory approvals in diagnostics. Thermo Fisher also strengthened its strategic position through partnerships, including a collaboration with OpenAI to expand AI use across operations and products.
Capital deployment was a key theme in 2025, with approximately $16.5 billion deployed, including $13 billion in acquisitions and $3.6 billion returned to shareholders via buybacks and dividends. Management said the company enters 2026 from a position of strength, supported by its growth strategy, operational discipline, and expanding capabilities across biopharma, diagnostics, and scientific research.
